Document is current
Any future updates will be listed below
-
Authors
Fløisand, Yngvar https://orcid.org/0000-0001-7267-1944
Remberger, Mats
Bigalke, Iris
Josefsen, Dag
Vålerhaugen, Helen
Inderberg, Else Marit
Olaussen, Richard W.
Gjertsen, Bjørn Tore https://orcid.org/0000-0001-9358-9704
Goedkoop, Rene
Geiger, Christiane
Prinz, Petra U.
Schnorfeil, Frauke M.
Pinkernell, Kai
Schendel, Dolores J. https://orcid.org/0000-0003-2466-2976
Kvalheim, Gunnar
-
Funding
Funding for this research was provided by:
Medigene Immunotherapies GmbH sponsored clinical trial and the associated research was paid by the company
- License Information
-
More Information
Article History
Received: 16 January 2023
Revised: 7 June 2023
Accepted: 19 July 2023
First Online: 28 July 2023
Competing interests
: CG, PP, and DJS are employees of Medigene Immunotherapies GmbH/Medigene AG which hold commercial interests in DC vaccines and served as Sponsor of this study. KP and FMS are previous employees of Medigene Immunotherapies GmbH/Medigene AG and RG is a consultant to Medigene AG.
